Comparison of catalytical activity and stereoselectivity between the recombinant human cytochrome P450 2D6.1 and 2D6.10

被引:3
|
作者
Kong, L. M.
Qian, M. R. [2 ]
Hu, H. H.
Xu, S. Y.
Yu, L. S.
Jiang, H. D.
Chen, S. Q.
Zeng, S. [1 ]
机构
[1] Zhejiang Univ, Dept Pharmaceut Anal & Drug Metab, Coll Pharmaceut Sci, Hangzhou 310058, Zhejiang, Peoples R China
[2] Zhejiang Acad Agr Sci, Inst Qual Stand Agr Prod, Hangzhou, Zhejiang, Peoples R China
来源
PHARMAZIE | 2012年 / 67卷 / 05期
关键词
IN-VITRO; CYP2D6; METABOLISM; PROPRANOLOL; IMIPRAMINE; EXPRESSION; ENZYMES; CYP1A2; SYSTEM;
D O I
10.1691/ph.2012.1128
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Polymorphisms of the cytochrome P450 2D6 (CYP2D6) gene play a major role in pharmacokinetic variability in human, while CYP2D6*10 is an important subtype in Asian people. In this study, the co-expression enzyme of human recombinant CYPOR, CYPb5 and CYP2D6.1 or CYP2D6.10 with the Bac-to-Bac (TM) system in baculovirus-infected insect cells was used to study the catalytical activity to imipramine metabolism and stereoselective metabolism of propranolol. The metabolites of imipramine were identified of hydroxyl imipramine and desipramine by LC-MS/MS. There are some differences between CYP2D6.1 and CYP2D6.10 activity. The kinetics parameters K-m, V-max, and CLint are 11.77 +/- 0.91 mu mol/L, 0.4235 +/- 0.05 nmol/nmol CYP2D6.1/min and 3.60 x 10(-5) ml/min/nmol CYP2D6.1 (n = 3) for CYP2D6.1, respectively, and 9.05 +/- 0.87 mu mol/L, 0.42 +/- 0.03 nmol/nmol CYP2D6.10/min, and 4.60 x 10(-5) ml/min/nmol CYP2D6.10 (n = 3) for CYP2D6.10. For propranolol, two metabolites were identified to be hydroxyl and N-desisopropylation propranolol by LC-MS/MS. When the substrate concentration was 0.20 mu mol/L, CYP2D6.1 and CYP2D6.10 exhibited significant stereoseletivity. Furthermore, enan-tioselective formation has been detected. Both of CYP2D6.1 and CYP2D6.10 produced more hydroxyl propranolol from the R-(+)-isomer than from the S-(-)-isomer while there was no obvious difference for N-desisopropylation propranolol production between R-(+)- and S-(-)- isomer. In summary, there is a some-what different catalytical activity and stereoselectivity between the human recombinant CYP2D6.1 and CYP2D6.10. The data we got will be helpful in preclinical research and clinical use of CYP2D6 substrates.
引用
收藏
页码:440 / 447
页数:8
相关论文
共 50 条
  • [41] Cytochrome P450 2J2 is required for the natural compound austocystin D to elicit cancer cell toxicity
    Kojima, Yukiko
    Fujieda, Saki
    Zhou, Liya
    Takikawa, Masahiro
    Kuramochi, Kouji
    Furuya, Toshiki
    Mizumoto, Ayaka
    Kagaya, Noritaka
    Kawahara, Teppei
    Shin-ya, Kazuo
    Dan, Shingo
    Tomida, Akihiro
    Ishikawa, Fuyuki
    Sadaie, Mahito
    CANCER SCIENCE, 2024, 115 (09) : 3054 - 3066
  • [42] Psychotropic medications and cytochrome P450 2D6 pharmacokinetic considerations in the elderly
    Shulman, RW
    Ozdemir, V
    CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE, 1997, 42 : S4 - S9
  • [43] Identifying the Dominant Contribution of Human Cytochrome P450 2J2 to the Metabolism of Rivaroxaban, an Oral Anticoagulant
    Zhao, Tingting
    Chen, Yanwei
    Wang, Dalong
    Wang, Liyan
    Dong, Peipei
    Zhao, Shan
    Wang, Changyuan
    Meng, Qiang
    Sun, Huijun
    Liu, Kexin
    Wu, Jingjing
    CARDIOVASCULAR DRUGS AND THERAPY, 2022, 36 (01) : 121 - 129
  • [44] Rational Molecular Design of a Fluorescent Probe for Selectively Sensing Human Cytochrome P450 2D6
    Ning, Jing
    Tian, Zhenhao
    Wang, Jiayue
    Yan, Fei
    Shi, Chao
    Zhang, Shujing
    Feng, Lei
    Shu, Xiaohong
    Cui, Jingnan
    James, Tony D.
    Ma, Xiaochi
    ANGEWANDTE CHEMIE-INTERNATIONAL EDITION, 2024, 63 (41)
  • [45] Effects of multi-kinase inhibitors on the activity of cytochrome P450 2J2
    Kojima, Ayaka
    Nadai, Masayuki
    Murayama, Norie
    Yamazaki, Hiroshi
    Katoh, Miki
    XENOBIOTICA, 2022, 52 (07) : 669 - 675
  • [46] Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients
    Rae, J. M.
    Sikora, M. J.
    Henry, N. L.
    Li, L.
    Kim, S.
    Oesterreich, S.
    Skaar, T. C.
    Nguyen, A. T.
    Desta, Z.
    Storniolo, A. M.
    Flockhart, D. A.
    Hayes, D. F.
    Stearns, V.
    PHARMACOGENOMICS JOURNAL, 2009, 9 (04) : 258 - 264
  • [47] Substrate specific metabolism by polymorphic cytochrome P450 2D6 alleles
    Bogni, A
    Monshouwer, M
    Moscone, A
    Hidestrand, M
    Ingelman-Sundberg, M
    Hartung, T
    Coecke, S
    TOXICOLOGY IN VITRO, 2005, 19 (05) : 621 - 629
  • [48] Evaluation of biotransformation capacity of transplastomic plants and hairy roots of Nicotiana tabacum expressing human cytochrome P450 2D6
    Sheludko, Y., V
    Gerasymenko, I. M.
    Herrmann, F. J.
    Warzecha, H.
    TRANSGENIC RESEARCH, 2022, 31 (03) : 351 - 368
  • [49] Potential of 4′-(p-Toluenesulfonylamide)-4-hydroxychalcone to Inhibit the Human Cytochrome P450 2J2 Isoform
    Lee, Boram
    Kang, Wonku
    Shon, Jongcheol
    Park, Ki Hun
    Song, Kyung-Sik
    Liu, Kwang-Hyeon
    JOURNAL OF THE KOREAN SOCIETY FOR APPLIED BIOLOGICAL CHEMISTRY, 2014, 57 (01): : 31 - 34
  • [50] Oxidation of Naringenin, Apigenin, and Genistein by Human Family 1 Cytochrome P450 Enzymes and Comparison of Interaction of Apigenin with Human P450 1B1.1 and Scutellaria P450 82D.1
    Nagayoshi, Haruna
    Murayama, Norie
    Kim, Vitchan
    Kim, Donghak
    Takenaka, Shigeo
    Yamazaki, Hiroshi
    Guengerich, F. Peter
    Shimada, Tsutomu
    CHEMICAL RESEARCH IN TOXICOLOGY, 2023, 36 (11) : 1778 - 1788